AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01144676
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
Trial: NCT00355576
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
Trial: NCT00355576
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 g BID for either study arm
Trial: NCT00355576
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
Trial: NCT03147586
Drug: Bio-tech and omega-3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
Trial: NCT03147586
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00824382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs delivered by the RespimatÂ® inhaler
Trial: NCT01124552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT03977753
Drug: 2LVERU® or 2LVERU® JUNIOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT03977753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT01852331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
Trial: NCT00749944
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
Trial: NCT00000617
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01721694
Drug: azithromycin 1.5%/Loteprednol 0,5% + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop, AO, QID
Trial: NCT01721694
Drug: azithromycin 1.5% + Loteprednol 0,5% (separately)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop, QID, AO
Trial: NCT00000250
Drug: 40% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
Trial: NCT00342563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01544959
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
Trial: NCT00697541
Drug: Advanced Eye Relief
RxNorm normalized name: Advanced Eye Relief Dry Eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
Trial: NCT01859793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in appearance given once/day orally
Trial: NCT02013336
Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT00058968
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03966456
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Trial: NCT00326781
Drug: Nicoderm Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
Trial: NCT03192995
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 20 mg. tablet
Trial: NCT03361865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice daily.
Trial: NCT00079586
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin per institutional practice
Trial: NCT01513902
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Trial: NCT01513902
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Trial: NCT01513902
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
Trial: NCT01424514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intra nasal
Trial: NCT00546117
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Solutab in 15 and 30 mg dosages.
Trial: NCT03048123
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin,leucovorin and 5-FU
Trial: NCT03048123
Drug: TACE Drug Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Trial: NCT01768975
Drug: OLT1177 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
Trial: NCT00088959
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02227316
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Uterine fibroid embolization
Trial: NCT02227316
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine fibroid embolization
Trial: NCT02227316
Drug: Intravenous placebo/Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine fibroid embolization
Trial: NCT01323153
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
Trial: NCT00451295
Drug: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Trial: NCT00451295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Trial: NCT02351908
Drug: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351908
Drug: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351908
Drug: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04319081
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are included after PCSK9 inhibitors prescription , at the first dispensation
Trial: NCT02775877
Drug: HMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003152
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03634436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Trial: NCT02872857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match drug capsules.
Trial: NCT05901350
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
Trial: NCT03675295
Drug: Hyalase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
Trial: NCT00035295
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01671150
Drug: endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Trial: NCT01311518
Drug: Drug: Injectable Thymosin beta 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
Trial: NCT01029704
Drug: Placebo capsules to match EGT0001442
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
Trial: NCT00002701
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002701
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002701
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002701
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02068170
Drug: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219570
Drug: clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00419601
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
Trial: NCT02395640
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 po d1-14
Trial: NCT00559299
Drug: GSK163090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00674466
Drug: 1.5 mg or 2.0 mg CJC-1134-PC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice-a-week
Trial: NCT00674466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice-a-week
Trial: NCT02273375
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03408470
Drug: [14C]-TD-1473 IV bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Intervention description included in arm description)
Trial: NCT03408470
Drug: [14C]-TD-1473 Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Intervention description included in arm description)
Trial: NCT00003764
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00438100
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
Trial: NCT02339116
Drug: fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02316899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily
Trial: NCT04560283
Drug: Vaginal gel HYALOGYN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
Trial: NCT02733731
Drug: Chinese Herbal Compound Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02733731
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02280759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consists of an identical formulation, except active substance
Trial: NCT02134626
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg / pill, one pill orally once a day for three months
Trial: NCT02134626
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01655082
Drug: V0116 transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One patch per day (during 24 hours) for 21 days
Trial: NCT02350946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03540303
Drug: CAR19 T cells carrying cytoplasmic activated PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Trial: NCT03633799
Drug: VeraCept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
Trial: NCT00078832
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimidex placebo
Trial: NCT00101075
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02122770
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN4924 intravenous solution.
Trial: NCT00483106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken orally twice a day for 7 consecutive days
Trial: NCT00904085
Drug: Oxymorphone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg
Trial: NCT00380081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Trial: NCT00132938
Drug: telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02345460
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02345460
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02280616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet twice daily AND 5ml placebo suspension twice daily
Trial: NCT02048917
Drug: High Intensity Counseling + Long Acting NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity Counseling + Long Acting NRT
Trial: NCT02048917
Drug: Low Intensity Counseling + Long Acting NRT + PRN NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Counseling + Long Acting NRT + PRN NRT
Trial: NCT02048917
Drug: Low Intensity Counseling + Long Acting NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Counseling + Long Acting NRT
Trial: NCT02309892
Drug: L-DOS47
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
Trial: NCT00721344
Drug: Technosphere Inhalation Powder (FDKP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere® Inhalation Powder 20mg
Trial: NCT00721344
Drug: Technosphere Inhalation Powder (FDKP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere® Inhalation Powder 40mg
Trial: NCT00721344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cartridges
Trial: NCT03026140
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
Trial: NCT00947661
Drug: SPARC0912
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops, once daily, 12 weeks
Trial: NCT00947661
Drug: Reference0912
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops, once daily, 12 weeks
Trial: NCT01317797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered three times, subcutaneous in the abdomen
Trial: NCT02339129
Drug: SST-0225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Trial: NCT02339129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Trial: NCT00500604
Drug: Irbesartan/hydrochlorothiazide
RxNorm normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/12.5mg tablet and 300/12.5mg tablet
Trial: NCT00500604
Drug: Valsartan/hydrochlorothiazide
RxNorm normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/12.5mg tablet and 160/12.5mg tablet
Trial: NCT04506905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of dose-matched placebo to MK-8189 according to randomization
Trial: NCT02957968
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 once every 2 weeks for 4 cycles.
Trial: NCT02957968
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.